Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Protocol for the mixed-methods process and context evaluation of the TB & Tobacco randomised controlled trial in Bangladesh and Pakistan: a hybrid effectiveness-implementation study

M. Boeckmann, I. Nohavova, O. Dogar, E. Kralikova, A. Pankova, K. Zvolska, R. Huque, R. Fatima, M. Noor, H. Elsey, A. Sheikh, K. Siddiqi, D. Kotz, . ,

. 2018 ; 8 (3) : e019878. [pub] 20180330

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu protokol klinické studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012747

INTRODUCTION: Tuberculosis (TB) remains a significant public health problem in South Asia. Tobacco use increases the risks of TB infection and TB progression. The TB& Tobacco placebo-controlled randomised trial aims to (1) assess the effectiveness of the tobacco cessation medication cytisine versus placebo when combined with behavioural support and (2) implement tobacco cessation medication and behavioural support as part of general TB care in Bangladesh and Pakistan. This paper summarises the process and context evaluation protocol embedded in the effectiveness-implementation hybrid design. METHODS AND ANALYSIS: We are conducting a mixed-methods process and context evaluation informed by an intervention logic model that draws on the UK Medical Research Council's Process Evaluation Guidance. Our approach includes quantitative and qualitative data collection on context, recruitment, reach, dose delivered, dose received and fidelity. Quantitative data include patient characteristics, reach of recruitment among eligible patients, routine trial data on dose delivered and dose received, and a COM-B ('capability', 'opportunity', 'motivation' and 'behaviour') questionnaire filled in by participating health workers. Qualitative data include semistructured interviews with TB health workers and patients, and with policy-makers at district and central levels in each country. Interviews will be analysed using the framework approach. The behavioural intervention delivery is audio recorded and assessed using a predefined fidelity coding index based on behavioural change technique taxonomy. ETHICS AND DISSEMINATION: The study complies with the guidelines of the Declaration of Helsinki. Ethics approval for the study and process evaluation was granted by the University of Leeds (qualitative components), University of York (trial data and fidelity assessment), Bangladesh Medical Research Council and Bangladesh Drug Administration (trial data and qualitative components) and Pakistan Medical Research Council (trial data and qualitative components). Results of this research will be disseminated through reports to stakeholders and peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER: ISRCTN43811467; Pre-results.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012747
003      
CZ-PrNML
005      
20190411093145.0
007      
ta
008      
190405s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/bmjopen-2017-019878 $2 doi
035    __
$a (PubMed)29602847
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Boeckmann, Melanie $u Institute of General Practice, Addiction Research and Clinical Epidemiology Unit, Medical Faculty of the Heinrich-Heine-University, Düsseldorf, Germany.
245    10
$a Protocol for the mixed-methods process and context evaluation of the TB & Tobacco randomised controlled trial in Bangladesh and Pakistan: a hybrid effectiveness-implementation study / $c M. Boeckmann, I. Nohavova, O. Dogar, E. Kralikova, A. Pankova, K. Zvolska, R. Huque, R. Fatima, M. Noor, H. Elsey, A. Sheikh, K. Siddiqi, D. Kotz, . ,
520    9_
$a INTRODUCTION: Tuberculosis (TB) remains a significant public health problem in South Asia. Tobacco use increases the risks of TB infection and TB progression. The TB& Tobacco placebo-controlled randomised trial aims to (1) assess the effectiveness of the tobacco cessation medication cytisine versus placebo when combined with behavioural support and (2) implement tobacco cessation medication and behavioural support as part of general TB care in Bangladesh and Pakistan. This paper summarises the process and context evaluation protocol embedded in the effectiveness-implementation hybrid design. METHODS AND ANALYSIS: We are conducting a mixed-methods process and context evaluation informed by an intervention logic model that draws on the UK Medical Research Council's Process Evaluation Guidance. Our approach includes quantitative and qualitative data collection on context, recruitment, reach, dose delivered, dose received and fidelity. Quantitative data include patient characteristics, reach of recruitment among eligible patients, routine trial data on dose delivered and dose received, and a COM-B ('capability', 'opportunity', 'motivation' and 'behaviour') questionnaire filled in by participating health workers. Qualitative data include semistructured interviews with TB health workers and patients, and with policy-makers at district and central levels in each country. Interviews will be analysed using the framework approach. The behavioural intervention delivery is audio recorded and assessed using a predefined fidelity coding index based on behavioural change technique taxonomy. ETHICS AND DISSEMINATION: The study complies with the guidelines of the Declaration of Helsinki. Ethics approval for the study and process evaluation was granted by the University of Leeds (qualitative components), University of York (trial data and fidelity assessment), Bangladesh Medical Research Council and Bangladesh Drug Administration (trial data and qualitative components) and Pakistan Medical Research Council (trial data and qualitative components). Results of this research will be disseminated through reports to stakeholders and peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER: ISRCTN43811467; Pre-results.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a výzkumný projekt $7 D012107
650    12
$a kouření $x škodlivé účinky $7 D012907
650    _2
$a tabák $7 D014026
650    12
$a tuberkulóza $x epidemiologie $7 D014376
651    _2
$a Bangladéš $7 D001459
651    _2
$a Pákistán $7 D010154
655    _2
$a protokol klinické studie $7 D000078325
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nohavova, Iveta $u University Hospital Prague VFN v. PRAZE, Prague, Czech Republic.
700    1_
$a Dogar, Omara $u Department of Health Sciences, University of York, York, UK.
700    1_
$a Kralikova, Eva $u University Hospital Prague VFN v. PRAZE, Prague, Czech Republic.
700    1_
$a Pankova, Alexandra $u University Hospital Prague VFN v. PRAZE, Prague, Czech Republic.
700    1_
$a Zvolska, Kamila $u University Hospital Prague VFN v. PRAZE, Prague, Czech Republic.
700    1_
$a Huque, Rumana $u ARK Foundation, Dhaka, Bangladesh.
700    1_
$a Fatima, Razia $u National Tuberculosis Control Programme (NTP), Islamabad, Pakistan.
700    1_
$a Noor, Maryam $u The Initiative, Islamabad, Pakistan.
700    1_
$a Elsey, Helen $u Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
700    1_
$a Sheikh, Aziz $u Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
700    1_
$a Siddiqi, Kamran $u Department of Health Sciences, University of York, York, UK.
700    1_
$a Kotz, Daniel $u Institute of General Practice, Addiction Research and Clinical Epidemiology Unit, Medical Faculty of the Heinrich-Heine-University, Düsseldorf, Germany. Department of Family Medicine, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.
700    1_
$a ,
773    0_
$w MED00184484 $t BMJ open $x 2044-6055 $g Roč. 8, č. 3 (2018), s. e019878
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29602847 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190411093203 $b ABA008
999    __
$a ok $b bmc $g 1392057 $s 1051052
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 8 $c 3 $d e019878 $e 20180330 $i 2044-6055 $m BMJ open $n BMJ Open $x MED00184484
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace